Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review  by Fogarty, Charles M et al.
Telithromycin in the treatment of pneumococcal
community-acquired respiratory tract
infections: a review
Charles M Fogarty a,*, Patricia Buchanan b, Michel Aubier c, Malik Baz d,
Dirkie van Rensburg e, Manickam Rangaraju f, Roomi Nusrat g
International Journal of Infectious Diseases (2006) 10, 136—147
http://intl.elsevierhealth.com/journals/ijida Spartanburg Pharmaceutical Research, 126 Dillon Street, Spartanburg, SC 29307 USA
bRiver Road Medical Group, Eugene, Oregon, USA
c Xavier Bichat School of Medicine, Paris, France
dABM Research Institute, Fresno, California, USA
eMedpark Centre, Witbank, South Africa
fAventis, Romainville, France
gAventis, Bridgewater, New Jersey, USA
Received 10 March 2003; received in revised form 12 January 2005; accepted 13 January 2005








Objectives: A pooled analysis of 14 Phase III studies was performed to establish the
clinical and bacteriologic efficacy of telithromycin 800 mg once daily in the treatment
of pneumococcal community-acquired respiratory tract infections (RTIs).
Methods: Data were examined from 5534 adult/adolescent patients with commu-
nity-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), or
acute bacterial sinusitis, who had received telithromycin for 5—10 days or a com-
parator antibacterial.
Results: Streptococcus pneumoniae was identified in 704/2060 (34.2%) bacteriolo-
gically evaluable patients. The respective per-protocol clinical cure rates for teli-
thromycin and comparators were 94.3% and 90.0% (CAP); 81.5% and 78.9% (AECB);
90.1% and 87.5% (acute sinusitis); 92.7% and 87.6% (all indications). Clinical cure rates
were 28/34 (82.4%) and 5/7, respectively, for penicillin-resistant infections, and 44/
52 (84.6%) and 11/14, respectively, for erythromycin-resistant infections. Of 82
patients with pneumococcal bacteremia, 74 (90.2%) were clinically cured after
telithromycin treatment, including 5/7 and 8/10 with penicillin- or erythromycin-
resistant strains, respectively. Adverse events considered possibly related to study
medication were reported by 1071/4045 (26.5%) telithromycin and 505/1715 (29.4%)* Corresponding author. Tel.: +1 864 583 1556; fax: +1 864 583 2292.
1201-9712/$32.00 # 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Community-acquired respiratory tract infections
(RTIs) such as community-acquired pneumonia
(CAP), acute bacterial exacerbations of chronic
bronchitis (AECB), and acute sinusitis are among
the most common diseases in industrialized coun-
tries, and are associated with a massive consump-
tion of healthcare resources.1 The total annual cost
of treatment of CAP is US$8.4 billion in the USA
alone,2 and CAP is responsible for approximately 4.5
million visits to physicians’ offices, emergency
departments, and outpatient clinics annually. In
comparison, the total annual treatment cost for
AECB in the USA is approximately US$1.6 billion.3
For both these diseases, more than three-quarters
of the annual treatment cost is accounted for by
inpatient care. An estimate for 1996 indicated that
the overall direct healthcare expenditure attribu-
table to sinusitis in the USA was US$5.8 billion.4
In addition to this appreciable socioeconomic
burden, community-acquired RTIs are associated
with considerable morbidity, and can be fatal in
vulnerable individuals if left untreated.5—9 Despite
the high prevalence of viral disease, a substantial
proportion of RTIs are still bacterial.6,8,10,11 These
infections require prompt attention with effective
therapies to shorten the duration of symptoms,
prevent progression to severe disease, eradicate
the causative pathogen(s), and — importantly —
prevent serious and sometimes life-threatening
complications such as bacteremia, meningitis, and
sepsis.
Streptococcus pneumoniae is the most common
causative bacterial pathogen identified in commu-
nity-acquired RTIs, accounting for 20—60% of CAP
cases12 (including around two-thirds of all cases of
bacteremic pneumonia6), 15—22% of AECB cases,10
and up to 54% of acute bacterial sinusitis cases.11,13
Patients with these infections are typically treated
empirically, so it is important that first-line thera-
pies can be relied upon to eradicate S. pneumoniae
as well as the other common pathogens seen in this
setting (Haemophilus influenzae, Moraxella catar-
rhalis, and atypical/intracellular organisms such as
Chlamydophila [Chlamydia] pneumoniae, Myco-
plasma pneumoniae, and Legionella spp.). Recentsurveillance studies have documented alarming
rises in global pneumococcal resistance to a variety
of antibacterials in common use, including current
first-line b-lactams and macrolides.14,15 Although
there is little clinical evidence to suggest that these
agents should not still be used to treat RTIs, agents
with a spectrum of activity covering resistant strains
may be expected not only to minimize the risk of
poor clinical outcome and potentially fatal purulent
complications, but also to lessen any potential con-
tribution to the growing resistance that may limit
empiric treatment options.
Telithromycin is the first of a new class of anti-
bacterials — the ketolides — to be approved for
clinical use in the first-line treatment of commu-
nity-acquired RTIs. This agent has a spectrum of
activity that specifically targets common bacterial
respiratory pathogens (S. pneumoniae [including
isolates resistant to erythromycin and/or penicil-
lin], Streptococcus pyogenes, H. influenzae and M.
catarrhalis,16,17 and atypical/intracellular organ-
isms18,19). The efficacy and safety of telithromycin
800 mg once daily in patients with community-
acquired RTIs have been studied in 16 Phase III
clinical trials20—35, many of which compared the
drug with one of a number of antibacterials
regarded as representative of current standards of
care. These included cefuroxime axetil, high-dose
amoxicillin or amoxicillin—clavulanate, penicillin V
(for tonsillopharyngitis), and new-generation
macrolides and quinolones. This paper presents a
pooled analysis of 14 of these studies (excluding
tonsillopharyngitis studies as no patients had pneu-
mococcal infection), which specifically assessed the
clinical and bacteriologic efficacy of telithromycin
in community-acquired RTIs caused by S. pneumo-
niae — the most common and potentially serious
bacterial cause of such infections.Methods
Patients and bacteriologic methods
The 14 Phase III studies involved a total of 5534 adult
(>18 years) or adolescent (13—18 years) patients
who had been treated for CAP (mild to moderatecomparator recipients. These events were generally of mild/moderate severity, and
mainly gastrointestinal in nature.
Conclusions: As S. pneumoniae is the leading bacterial cause of community-acquired
RTIs, and antibacterial resistance is increasing among this species, these findings
support the use of telithromycin as first-line therapy in this setting.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
138 C.M. Fogarty et al.severity), AECB, or acute bacterial sinusitis
(Table 1). Patients received either oral telithromy-
cin 800 mg (2  400 mg capsules) once daily
(n = 881) for 5—10 days (depending on the condition
being treated) or a comparator antibacterial agent
(n = 1653) that was first-line at the time of the study
(see Table 1 for details of individual drugs and
regimens). The nine studies that included a com-
parator arm were of a randomized, double-blind
design, with all comparator drugs given as 10- or
7- to 10-day courses (Table 1). All studies were
carried out in accordance with the provisions of
the latest revisions of the Declaration of Helsinki
and were in compliance with Good Clinical Practice
regulations. Protocols were approved by the rele-
vant ethics committees at each institution, andTable 1 Summary of 14 clinical trials of telithromycin 800 m








3001 (10 days) 22 199/62 32
3006 (10 days) 34 204/48 25
3009 (7—10 days) 31 100/32 11




3010 (7 days) 20 418/255 76
3012 (7 days) 35 538/265 110
Acute exacerbations of chronic bronchitis
3003 (5 days) 21 160/50 12
3007 (5 days) 33 182/32 3
3013 (5 days) 29 270/90 14
Acute sinusitis
3002 (5 or 10 days)24 335/201 70
3005 (5 or 10 days)30 405/18 6
3011 (5 days) 27 240/126 37
Totals 3881/1578 555
AMC, amoxicillin—clavulanate; AMX, amoxicillin; bid, twice daily
population; CLA, clarithromycin; CXM, cefuroxime axetil; mITT, m
trovafloxacin.
a As either the sole pathogen or in combination with another patwritten informed consent was obtained from all
participants before enrollment.
Pathogens were isolated from blood, respiratory
secretion, or sinus aspirate cultures. The respiratory
pathogens isolated from these samples and consid-
ered by the examining investigator to be responsible
for infection were defined as causative organisms.
Strains of S. pneumoniae isolated from sample
cultures were tested for their susceptibility to
penicillin, erythromycin, and telithromycin by
determination of minimum inhibitory concentra-
tions (MICs) and disk zone inhibition at a central
reference laboratory using National Committee for
Clinical Laboratory Standards (NCCLS) recom-
mended criteria and methodology.36,37 Intermedi-
ate susceptibility to penicillin was defined as an MICg once daily in patients with pneumococcal community-
Comparator





AMX 1 g tid
(10 days)
205/63 34
CLA 500 mg bid
(10 days)
212/45 23
TVA 200 mg daily
(7—10 days)
104/34 9









CXM 500 mg bid
(10 days)
191/35 7











; bmITT, bacteriologically evaluable modified intent to treat
odified intent to treat population; tid, three-times daily; TVA,
hogen(s).
Telithromycin in pneumococcal RTIs 139of 0.12—1.0 mg/L; strains with MICs  2.0 mg/L
were considered resistant and those with MICs 
0.06 mg/L were considered susceptible. Resistance
to erythromycin was defined as an MIC of 1.0 mg/
L; susceptibility was defined as an MIC  0.25 mg/L.
Susceptibility to telithromycin was defined using
tentative NCCLS breakpoints (as approved by the
Subcommittee on Antimicrobial Testing, January
2003): MIC  1.0 mg/L (susceptible); MIC 2.0 mg/L
(intermediate); and MIC  4.0 mg/L (resistant).
Clinical and bacteriologic outcomes
Clinical and bacteriologic outcomes were assessed
during a post-therapy/test of cure visit that took
place between Days 17 and 24 (as shown in the
generalized study design depicted in Figure 1). This
visit took place after the end of therapy visit (Days
10—13) to allow early relapses to be counted as
failures and thus provides a rigorous test of anti-
bacterial efficacy.
The primary objective of the comparator-con-
trolled studies was to demonstrate equivalence in
clinical efficacy of telithromycin and comparator
antibacterial treatment at the post-therapy/test
of cure visit in the per-protocol population. The
primary objective of the noncomparative studies
was to demonstrate clinical efficacy and enrich
the clinical trial database with additional informa-
tion regarding pathogens of interest. Clinical out-
come assessment was based on clinical signs,
symptoms, and X-ray findings, and classified as cure,
failure or indeterminate. Patients were classified as
cured if clinical signs and symptoms were assessed
as having returned to the preinfection state or
shown improvement and, for CAP patients, if X-
ray findings showed improvement or lack of progres-
sion. Subjects with unchanged or worsening symp-
toms or lack of clinical improvement requiring
additional antibiotics or subsequent treatment were
classified as failure. Satisfactory bacteriologic out-
come was defined as documented eradication of theFigure 1 Generalized design for Phascausative pathogen or clinical improvement to the
extent that a follow-up culture could not be
obtained and the pathogen was, therefore, pre-
sumed to be eradicated. Presumed bacterial failure
occurred when, by definition, clinical failure was
the outcome. Indeterminate clinical and bacterio-
logic responses were excluded from efficacy ana-
lyses.
Safety
Safety was evaluated at each visit on the basis of
physical examinations, vital signs, 12-lead electro-
cardiograms, and standard clinical laboratory tests.
Adverse events (AEs) reported by the patient or
observed by the investigator were recorded
throughout the study. AEs included any sign, symp-
tom, syndrome, or illness that appeared or wor-
sened in a patient during the period of clinical
observation, and which may have impaired the
well-being of the patient. These events included
all laboratory findings or results of other diagnostic
procedures that were considered to be clinically
relevant. Clinically noteworthy abnormal laboratory
values were those values considered medically
important by the study sponsor according to pre-
defined criteria. The investigator recorded the nat-
ure and severity (mild, moderate, severe) of any AE,
as well as the time of onset, time course of the
effects, and relation to study treatment.
Data analysis
All patients with a confirmed diagnosis of the dis-
ease indicated for therapy in each study who
received at least one dose of study medication were
included in the modified intent to treat (mITT)
population. The bacteriologically evaluable mITT
(bmITT) population included all mITT patients with
a microbiologically confirmed pathogen isolated at
study entry. Patients with no major protocol devia-
tions after randomization were evaluated clinicallye III studies of telithromycin (TEL).
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Table 2 Key demographics and baseline infection
characteristics across all studies for patients infected
with S. pneumoniae as the sole pathogen or in combi-
nation with another pathogen(s) (bmITT population).






Male 341 (61.4) 84 (56.4)
Female 214 (38.6) 65 (43.6)
Age (years)
13—18 10 (1.8) 2 (1.3)
>18—<65 481 (86.7) 121 (81.2)
65 64 (11.5) 26 (17.4)
Ethnicity
White 348 (62.7) 101 (67.8)
Black 157 (28.3) 36 (24.2)
Asian/Oriental 8 (1.4) 4 (2.7)
Other 42 (7.6) 8 (5.4)
Severityaon a per-protocol basis (PPc population). The bac-
teriologic per-protocol population (PPb) included all
patients in the per-protocol population who had a
causative pathogen isolated at the pre-therapy visit
and a classifiable bacteriologic response at the post-
therapy/test of cure visit. All patients who received
at least one dose of the study medication and who
had at least one safety assessment after the start of
treatment were included in the safety population.
Patients infected with S. pneumoniae were
pooled from all treated indications to form a sub-
group. Pooling of patients who received telithromy-
cin for 5—10 days for acute sinusitis and 7—10 days
for CAP (5 days in one CAP study) was permitted as
these regimens have been shown in previous studies
to be of equivalent clinical and bacteriologic effi-
cacy.24,25 Clinical and bacteriologic outcomes in
patients with pneumococcal infection, including
those with resistant strains, were determined. Stan-
dard errors of the mean were calculated for clinical
cure rates.Mild 106 (19.1) 20 (13.4)
Moderate 375 (67.6) 119 (79.9)
Severe 74 (13.3) 10 (6.7)
bmITT, bacteriologically evaluable modified intent to treat
population.
a As assessed by the investigator.Results
Patients
S. pneumoniae was identified as the sole pathogen
or in combination with another pathogen(s) in 704
patients — 34.2% of bacteriologically evaluable
patients (n = 2060, bmITT) and 12.7% of the total
patient population (n = 5534, mITT). Of this sub-
group with S. pneumoniae infections, 555 indivi-
duals received telithromycin and 149 were
treated with a comparator drug (bmITT population;
Table 1).
In these studies, the two treatment groups were
well matched with regard to sex and ethnicity
(Table 2). The majority of patients (>80%) in both
groups were adults aged >18 years, although there
was a slightly higher proportion of patients aged65
years in the comparator group than in the telithro-
mycin group (17.4% vs. 11.5%, respectively)
(Table 2). Most patients (68—80%) in both groups
had disease of moderate severity. However, the
proportion of patients with mild or severe disease
was slightly higher in the telithromycin group (19.1%
vs. 13.4% and 13.3% vs. 6.7%, respectively) and
there was a higher proportion of patients with
moderate disease in the comparator group (Table 2).
In vitro susceptibility
Of 495 pneumococcal isolates from respiratory sam-
ples and blood cultures taken from the telithromy-
cin-treated patients who underwent MIC evaluation(bmITT population), 493 (99.6%) were inhibited by
telithromycin at an MIC of 1 mg/L (modal MIC
0.008 mg/L). The remaining two strains, both of
which were resistant to penicillin and erythromycin,
had a telithromycin MIC of 2.0 mg/L.
A total of 94 patients (bmITT population) who
received telithromycin had positive blood cultures
for pneumococcal disease. All of these individuals
were treated for CAP, and all 83 isolates from this
group for which MICs were calculated were inhibited
by telithromycin at an MIC of 1 mg/L (modal MIC
0.008 mg/L).
Clinical and bacteriologic outcomes
The respective clinical cure rates for telithromycin
and comparator agents among PPb patients infected
with S. pneumoniae were: 94.3% (300/318) and
90.0% (63/70) [CAP]; 81.5% (22/27) and 78.9%
(15/19) [AECB]; 90.1% (82/91) and 87.5% (14/16)
[acute sinusitis] (Figure 2). These rates were gen-
erally comparable to the overall clinical cure rates
for each indication (Figure 2). Pooled clinical cure
rates for patients infected with S. pneumoniae (all
indications) were similar after telithromycin or
comparator treatment in both the PPb (92.7%
[404/436] vs. 87.6% [92/105]) and the bmITT popu-
lations (91.7% [473/516] vs. 85.8% [115/134],
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Figure 2 Clinical cure rates (improvement or return to preinfection state) in all patients and those with S. pneumoniae
infection at the post-therapy/test of cure visit after treatment with telithromycin 800 mg once daily or a comparator
antibacterial for community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), or acute
sinusitis (per-protocol [a] and modified intent to treat [b] populations).respectively). In addition, cure rates after treat-
ment with telithromycin vs. comparator in the over-
all patient populations were comparable (PPc:
88.5% [2774/3136] vs. 86.4% [1081/1251]; mITT:
81.3% [3156/3881] vs. 78.0% [1289/1653], respec-
tively).
Good clinical cure and bacteriologic eradication
rates were also reported with telithromycin in
patients with infections caused by S. pneumoniae
with reduced susceptibility to either penicillin and/
or erythromycin (Table 3). Clinical cure rates in
patients with isolates resistant to penicillin com-
pared favorably with comparators, 28/34 (82.4%)
and 5/7 for telithromycin and pooled comparators
(PPb population). Corresponding rates of satisfac-
tory bacteriologic outcome were 28/34 (82.4%) and
6/7, respectively. Clinical cure rates in patients with
erythromycin-resistant strains were 44/52 (84.6%)and 11/14 (78.6%) with telithromycin and pooled
comparators, respectively (PPb population). Similar
clinical cure patterns were seen in the bmITT popu-
lation. In patients with strains of S. pneumoniae
with reduced susceptibility to both penicillin and
erythromycin, clinical cure rates were 30/36
(83.3%) and 8/10, respectively (PPb population);
similar rates were again observed in the bmITT
population.
Of 82 patients with pneumococcal bacteremia
who were evaluable on a per-protocol basis, 74
(90.2%) were clinically cured and 77 (93.9%)
achieved a satisfactory bacteriologic outcome
(eradication or presumed eradication) after treat-
ment with telithromycin. The clinical cure and
satisfactory bacteriologic outcome rates in the
pooled comparator group for this category were
both 15/19 (78.9%). Clinical cure was achieved in
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Table 3 Rates of clinical curea and satisfactory bacteriologic outcomeb at post-therapy/test of cure visit after
treatment with either telithromycin 800 mg daily or a comparator antibacterial for community-acquired respiratory
tract infections caused by S. pneumoniaec with reduced susceptibility to either penicillin or erythromycin.









PEN-S 293/315 (93.0) 299/315 (94.9) 71/80 (88.8) 70/80 (87.5)
PEN-I 40/41 (97.6) 41/41 (100) 7/8 7/8
PEN-R 28/34 (82.4) 28/34 (82.4) 5/7 6/7
ERY-S 317/338 (93.8) 324/338 (95.9) 72/81 (88.9) 71/81 (87.7)
ERY-R 44/52 (84.6) 44/52 (84.6) 11/14 (78.6) 12/14 (85.7)
PEN-I/PEN-R + ERY-R 30/36 (83.3) 30/36 (83.3) 8/10 9/10
bmITT population
PEN-S 339/368 (92.1) 345/363 (95.0) 87/100 (87.0) 87/99 (87.9)
PEN-I 46/48 (95.8) 48/49 (98.0) 10/11 (90.9) 10/12 (83.3)
PEN-R 34/42 (81.0) 35/42 (83.3) 6/9 7/9
ERY-S 369/399 (92.5) 378/395 (95.7) 91/105 (86.7) 91/105 (86.7)
ERY-R 51/60 (85.0) 51/60 (85.0) 12/15 (80.0) 13/15 (86.7)
PEN-I/PEN-R + ERY-R 37/44 (84.1) 37/44 (84.1) 9/11 (81.8) 10/11 (90.9)
bmITT, bacteriologically evaluable modified intent to treat population; ERY-R, resistant to erythromycin (MIC 1.0 mg/L); ERY-S,
susceptible to erythromycin (MIC 0.25 mg/L); PEN-I, intermediate susceptibility to penicillin (MIC 0.12—1.0 mg/L); PEN-I/PEN-R,
not susceptible to penicillin (includes penicillin-intermediate and -resistant isolates); PEN-R, resistant to penicillin (MIC2.0 mg/L);
PEN-S, susceptible to penicillin (MIC 0.06 mg/L); PPb, bacteriologically evaluable per-protocol population.
a Clinical improvement or return to preinfection state.
b Documented or presumed eradication.
c As the sole pathogen or as part of a mixed infection.5/7 telithromycin-treated bacteremic patients
infected with penicillin-resistant isolates, and
8/10 patients with isolates resistant to erythromy-
cin, representing two clinical failures: S. pneumo-
niae isolated from these two patients were resistant
to both penicillin and erythromycin.
Safety
As shown in Figure 3, telithromycin had a safety and
tolerability profile for the five most common AEs
which was similar to those of comparators across the
pooled studies. Treatment-emergent AEs were
reported by 1746/4045 (43.2%) telithromycin reci-
pients and 835/1715 (48.7%) patients who received
comparator antibacterials. Treatment-emergent
AEs considered by investigators to be possibly
related to study medication were seen in 1071/
4045 (26.5%) and 505/1715 (29.4%) patients in the
two treatment groups, respectively. The most fre-
quently reported treatment-related AEs were diar-
rhea (telithromycin 7.6%; comparators 8.9%),
nausea (telithromycin 5.3%; comparators 4.4%),
and headache (telithromycin 1.5%; comparators
2.4%). Other treatment-related AEs included abnor-
mal liver function tests (telithromycin 1.8%[71/4045]; comparators 1.7% [29/1715]) and visual
disturbances, which occurred in 0.4% (15/4045) of
telithromycin patients and 0.2% (3/1715) of
comparator patients. In both groups, the AEs were
of mild to moderate intensity in the majority of
cases reported. Few patients in either treatment
group discontinued due to AEs (telithromycin 2.3%;
comparators 3.0%), and there were no treatment-
related deaths. There were few clinically
noteworthy abnormal laboratory values (167/4045
telithromycin-treated patients [4.0%] and 75/1715
comparator-treated patients [4.4%]), which
included assessment of cardiac (including QT inter-
val), liver, and renal function.
Discussion
This pooled analysis focused on the clinical and
bacteriologic efficacy of the new ketolide, telithro-
mycin, in 555 patients with predominantly mild to
moderate community-acquired pneumococcal RTIs
including CAP, AECB, and ABS. Overall, results from
the 14 trials confirm that this antibacterial, at a
dosage of 800 mg once daily, achieves high rates of
clinical cure and satisfactory bacteriologic outcome
in patients infected with S. pneumoniae, with effi-
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Figure 3 Frequencies of treatment-emergent adverse events (AEs) for telithromycin and comparator antibacterials by
indication. All events reported are presented, together with those considered by investigators to be possibly related to
study treatment and the five most common individual AEs possibly related to treatment.cacy equivalent to that seen with a range of stan-
dard first-line antibacterial agents.6,38—43 For all
indications combined, telithromycin achieved a
clinical cure rate of 93% in patients with pneumo-
coccal infections (PPb population); the correspond-
ing cure rate for comparator agents was 88%. Similar
results were seen in the more conservative analysis
of the bmITT population that includes protocolviolators and incomplete data. For each of the RTI
indications analyzed, the overall clinical cure rates
associated with telithromycin treatment (81.5%
[AECB]; 90.1% [acute sinusitis]; 94.3% [CAP]) were
higher than those seen with comparators (78.9%
[AECB]; 87.5% [acute sinusitis]; 90.0% [CAP]) in
the respective per-protocol patient populations.
Furthermore, clinical cure and bacteriologic eradi-
144 C.M. Fogarty et al.cation (eradication/presumed eradication) rates in
telithromycin patients with documented S. pneu-
moniae infection were similar to those reported for
the total patient population covered by the analysis.
The efficacy of telithromycin against S. pneumoniae
also extended to patients infected with strains with
reduced susceptibility to penicillin (12.8% of iso-
lates) and/or erythromycin (9.4% of isolates).
Although these results are based on low numbers
of isolates, they complement those from previous
analyses, demonstrating that telithromycin pro-
vides clinical and bacteriologic efficacy in infections
caused by common and atypical RTI pathogens,
including those caused by resistant pathogens.44—
47 The current analysis is limited by the fact that
data were pooled from 14 studies, each of which had
focused on one indication and treatment regimen.
The potential effects of variable treatment regi-
mens on clinical outcome were not addressed in this
study. Furthermore, any differences in efficacy
between telithromycin and individual comparators
would not be evident in the current analysis, as the
data for comparator agents were pooled.
As S. pneumoniae represents the leading bacter-
ial cause of community-acquired RTIs and is asso-
ciated with a high complication rate compared to
other pathogens, physicians prescribing empiric
therapy for such infections need to recognize the
importance of choosing an agent that can effec-
tively target this organism as well as other common
typical and atypical respiratory pathogens. At pre-
sent, b-lactams and macrolides are the most com-
monly used drugs for the first-line management of
community-acquired RTIs. However, the clinical
usefulness of these agents may be threatened by
the high and increasing prevalence of antibiotic
resistance, particularly among isolates of S. pneu-
moniae.15 Antibacterial susceptibility surveillance
programs have indicated significant levels of resis-
tance to penicillin and erythromycin among respira-
tory tract isolates of S. pneumoniae, with global
resistance rates of 22.1% (penicillin) and 31.1%
(erythromycin) reported in one study of respiratory
isolates collected between 1999 and 2000.14 The
quinolones are an attractive option for use against
resistant S. pneumoniae; however, as with other
antibiotics, occurrence of resistance is correlated
with their widespread use. Because of their broad
spectrum, some experts may recommend use of an
alternative antibiotic for first-line use in the com-
munity setting.
Emerging data from retrospective analyses and
case reports indicate that increasing pneumococcal
resistance may be compromising the efficacy of
current therapies in patients with community-
acquired RTIs to a greater extent than has beensuggested by the results of clinical trials.48 In recent
years, there have been several reports of bacter-
emia, breakthrough sepsis,49—52 or fatal outcome53—
55 associated with resistant pneumococcal strains in
patients with lower RTIs who were treated with
macrolides as first-line therapy. Other reports detail
macrolide treatment failure in CAP patients who
were subsequently treated successfully with other
antibacterial agents.56,57 Such treatment failures
may be explained, in part, by an inability of some
macrolides to achieve sufficiently high tissue con-
centrations at currently recommended dosages to
be effective against these pathogens, in an environ-
ment with increasingly higher erythromycin MICs.58
These observations of treatment failures suggest
that there is a need for new antibacterials, such
as telithromycin, which retain efficacy against anti-
biotic-resistant S. pneumoniae infections.
Telithromycin has a spectrum of activity allowing
first-line use against community-acquired RTIs, pro-
viding coverage of common and atypical bacterial
pathogens. Although structurally related to the
macrolides, it has a distinct microbiologic profile
— due to differences in its chemical structure — that
confers activity against resistant pneumococcal
strains. The most notable structural modification
is the replacement of the L-cladinose group with a
keto group at position C3 of the macrolactone ring
that enables telithromycin to bind to its target
without the associated inducible macrolide—linco-
samide—streptograminB (MLSB) resistance that
many respiratory pathogens now exhibit.59 In addi-
tion, a carbamate extension at positions C11 and 12
allows telithromycin to bind to wild-type ribosomes
with an affinity 10 times greater than that of ery-
thromycin and 6 times that of clarithromycin, and
its affinity for MLSB-resistant ribosomes is over 20
times greater than that of either macrolide.59 Once-
daily administration of telithromycin 800 mg is suf-
ficient to achieve drug concentrations in respiratory
tissues that exceed MICs for key pathogens such as S.
pneumoniae — including resistant strains — for up to
24 hours after each dose.60,61
Patients with CAP caused by S. pneumoniae are at
risk of progression to bacteremia and septic com-
plications, such as respiratory failure, meningitis,
pleural effusions, and empyema, which may be
fatal.54,62,63 With the outpatient treatment of mild
to moderate CAP, many patients are treated without
cultures being available. Although there is little
clinical evidence to indicate that current first-line
therapies should no longer be used to treat pneu-
mococcal RTIs, the rising incidence of resistance
among S. pneumoniae, and its association with
bacteremia, suggest that new options for first-line
therapy effective against resistant pneumococci
Telithromycin in pneumococcal RTIs 145may soon be needed. In the present analysis,
telithromycin showed high rates of clinical and
bacteriologic efficacy (>90%) in patients with pneu-
mococcal bacteremia, who represented more than
10% of those with a pneumococcal etiology. This
efficacy extended to those bacteremic patients with
penicillin- or erythromycin-resistant strains.
With regard to safety, telithromycin was well
tolerated in patients with CAP, AECB, and acute
sinusitis. The nature and frequency of AEs were
similar in the telithromycin and pooled comparator
groups. Most AEs were of mild to moderate severity
and very few patients withdrew because of AEs.
In conclusion, telithromycin 800 mg once daily
shows favorable clinical and bacteriologic efficacy
as well as good tolerability in the treatment of
community-acquired RTIs caused by S. pneumoniae
and other common respiratory tract pathogens. This
efficacy extends to patients with pneumococcal
bacteremia and to pneumococcal strains with
reduced susceptibility to penicillin and/or erythro-
mycin. Given that S. pneumoniae remains the major
bacterial cause of community-acquired RTIs, and
that penicillin and macrolide resistance are increas-
ing among this species, the findings of this pooled
analysis support the use of telithromycin as a first-
line empiric treatment in this setting.
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